|
Friday, February 17, 2023, San Francisco, California, 6:30 PM – 8:00 PM Pacific Time (9:30 PM – 11:00 PM Eastern Time)
Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Urothelial Bladder CancerPart 3 of a 3-Part CME Symposium Series Held in Conjunction with the 2023 ASCO Genitourinary Cancers Symposium
Location
San Francisco Marriott Marquis 780 Mission Street San Francisco, CA 94103 Hotel Phone: (415) 896-1600 Program Schedule — Pacific Time 6:15 PM – 6:30 PM — Registration 6:30 PM – 8:00 PM — Educational Dinner Meeting Meeting Room Yerba Buena – Salon 7 (Lower B2 Level) This event will also be webcast live. Please see Registration tab for details. Faculty
Matthew D Galsky, MD Professor of Medicine Icahn School of Medicine at Mount Sinai Co-Leader, Bladder Cancer Center of Excellence Associate Director, Translational Research The Tisch Cancer Institute New York, New York Jonathan E Rosenberg, MD Chief, Genitourinary Medical Oncology Service Division of Solid Tumor Oncology Enno W Ercklentz Chair Memorial Sloan Kettering Cancer Center New York, New York Arlene Siefker-Radtke, MD Professor Department of Genitourinary Medical Oncology Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, Texas Moderator Elisabeth I Heath, MD Associate Center Director, Translational Sciences Chair, Genitourinary Oncology Multidisciplinary Team Professor of Oncology and Medicine Hartmann Endowed Chair for Prostate Cancer Research Director, Prostate Cancer Research Karmanos Cancer Institute Wayne State University School of Medicine Detroit, Michigan This activity is supported by educational grants from Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.
Program Schedule — Pacific Time
6:15 PM – 6:30 PM — Registration 6:30 PM – 8:00 PM — Educational Dinner Meeting MODULE 1: Integrating Novel Treatment Strategies into the Management of Nonmetastatic Urothelial Bladder Cancer (UBC) — Dr Galsky
MODULE 2: Current and Future Front-Line Treatment for Metastatic UBC (mUBC) — Dr Rosenberg
MODULE 3: Selection and Sequencing of Therapy for Relapsed/Refractory mUBC — Dr Siefker-Radtke
MODULE 4: Novel Investigational Agents and Strategies in the Treatment of mUBC — Dr Heath
Target Audience
CME Credit Form FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Galsky — Advisory Committee: Aileron Therapeutics Inc, Alligator Bioscience, Astellas, AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, BioMotiv, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals Inc, Dracen Pharmaceuticals, Dragonfly Therapeutics, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Incyte Corporation, Infinity Pharmaceuticals Inc, Inovio Pharmaceuticals Inc, Janssen Biotech Inc, Lilly, Merck, Novartis, Numab Therapeutics AG, Pfizer Inc, Seagen Inc, UroGen Pharma; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Merck. Dr Rosenberg — Advisory Committee: Astellas, Seagen Inc, Tyra Biosciences; Consulting Agreements: Aadi Bioscience, Alligator Bioscience, Astellas, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Imvax Inc, Infinity Pharmaceuticals Inc, Jiangsu Hengrui Medicine Co Ltd, Lilly, Merck, Mirati Therapeutics Inc, Pfizer Inc, QED Therapeutics, Seagen Inc, Tyra Biosciences; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Seagen Inc; Honoraria: EMD Serono Inc, Pfizer Inc. Dr Siefker-Radtke — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bavarian Nordic, Bristol-Myers Squibb Company, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, IDEAYA Biosciences, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mirati Therapeutics Inc, Nektar, Seagen Inc, Taiho Oncology Inc; Contracted Research: Basilea Pharmaceutica Ltd, Bristol-Myers Squibb Company, Janssen Biotech Inc, Merck, Mirati Therapeutics Inc, Nektar, Takeda Pharmaceuticals USA Inc; Honoraria: Janssen Biotech Inc.MODERATOR — Elisabeth I Heath, MD – Advisory Committee: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Sanofi; Consulting Agreement: Astellas; Contracted Research: Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, BioXcel Therapeutics Inc, Calithera Biosciences, Caris Life Sciences, Corcept Therapeutics, Corvus Pharmaceuticals, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, F Hoffman-La Roche Ltd, Five Prime Therapeutics Inc, Fortis Therapeutics, Gilead Sciences Inc, GSK, Harpoon Therapeutics, Infinity Pharmaceuticals Inc, iTeos Therapeutics, Janssen Biotech Inc, Merck, Merck Sharp & Dohme LLC, Mirati Therapeutics Inc, Modra Pharmaceuticals, Oncolys BioPharma, Peloton Therapeutics Inc, a wholly-owned subsidiary of Merck & Co Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, POINT Biopharma, Seagen Inc; Honoraria: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Genzyme Corporation, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Seagen Inc; Speakers Bureau: Sanofi; Nonrelevant Financial Relationship: Calibr. RESEARCH TO PRACTICE PRESIDENT NEIL LOVE, MD — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. SupportersThis activity is supported by educational grants from Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC. San Francisco Marriott Marquis
This activity is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of urothelial bladder cancer. IN-PERSON registration for clinicians in practice/healthcare professionals
Thank you for your interest in our CME program. At this time online preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 6:00 PM PT on Friday, February 17th. If you are interested in attending, please visit our registration desk outside the Yerba Buena Ballroom – Salon 7 (Lower B2 Level) at the San Francisco Marriott Marquis hotel (780 Mission Street), within walking distance of the Moscone Convention Center (2 blocks). Please note: Seats will be offered on a first come, first served basis, and onsite registration does not guarantee participation in the meal service.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153. NOTICE: Registration for this event is independent of registration for the 2023 ASCO Genitourinary Cancers Symposium. LIVE WEBCAST registration for all professionals
Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. REGISTRATION FOR WEBCAST »Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
Not an official event of the 2023 ASCO Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation. |